Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Average (2020 - 2026)

Cytek Biosciences filings provide 6 years of Equity Average readings, the most recent being $360.2 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 7.79% to $360.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $360.2 million, a 7.79% decrease, with the full-year FY2025 number at $368.7 million, down 6.51% from a year prior.
  • Equity Average hit $360.2 million in Q4 2025 for Cytek Biosciences, down from $378.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $424.5 million in Q1 2023 to a low of -$7.5 million in Q1 2021.
  • Median Equity Average over the past 5 years was $391.9 million (2024), compared with a mean of $348.8 million.
  • Biggest five-year swings in Equity Average: surged 8298.01% in 2022 and later decreased 7.79% in 2025.
  • Cytek Biosciences' Equity Average stood at $404.3 million in 2021, then grew by 4.14% to $421.0 million in 2022, then fell by 3.97% to $404.3 million in 2023, then decreased by 3.39% to $390.6 million in 2024, then decreased by 7.79% to $360.2 million in 2025.
  • The last three reported values for Equity Average were $360.2 million (Q4 2025), $378.1 million (Q3 2025), and $378.6 million (Q2 2025) per Business Quant data.